Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
a largest » _ largest (Expand Search), a latest (Expand Search)
a large » _ large (Expand Search)
5 mean » 5 means (Expand Search), _ mean (Expand Search), a mean (Expand Search)
Showing 1 - 20 results of 4,867 for search '(( a largest decrease ) OR ((( a large decrease ) OR ( 5 mean decrease ))))', query time: 0.46s Refine Results
  1. 1
    Decadal mean regional hydrology.

    Decadal mean regional hydrology. by Nic Gedney (19762301)

    Published 2024
    Save to List
    Saved in:
  2. 2
    Contemporary mean inundation fraction in the Amazon basin.

    Contemporary mean inundation fraction in the Amazon basin. by Nic Gedney (19762301)

    Published 2024
    Save to List
    Saved in:
  3. 3
    Tissue, days post-infection (dpi) and the top 10 most significant genes with increased and decreased expression with valid gene symbols for the response contrasts.

    Tissue, days post-infection (dpi) and the top 10 most significant genes with increased and decreased expression with valid gene symbols for the response contrasts. by Gillian P. McHugo (8965919)

    Published 2025
    Save to List
    Saved in:
  4. 4
    Regional contemporary (1990–1999 mean) precipitation and JULES inundation fraction over the Amazon basin.

    Regional contemporary (1990–1999 mean) precipitation and JULES inundation fraction over the Amazon basin. by Nic Gedney (19762301)

    Published 2024
    Save to List
    Saved in:
  5. 5
    NSC population and proliferation decrease drastically during the second postnatal week of DG development.

    NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

    Published 2025
    Save to List
    Saved in:
  6. 6
    Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 <sup>a</sup> indicates ≥1.50 SD (16.8) from the mean (31.0), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 <sup>a</sup> indicates ≥1.50 SD (16.8) from the mean (31.0... by Luke R. Cavanah (19022435)

    Published 2025
    Save to List
    Saved in:
  7. 7
    Incorporating a social responsibility goal in the prompt causes overleverage in utilities (A) and decreases risk of low ESG rating (B) (Study 3).

    Incorporating a social responsibility goal in the prompt causes overleverage in utilities (A) and decreases risk of low ESG rating (B) (Study 3). by Philipp Winder (21615570)

    Published 2025
    Save to List
    Saved in:
  8. 8
    Innovation and night light in large and small cities.

    Innovation and night light in large and small cities. by Saul Estrin (8629173)

    Published 2024
    Save to List
    Saved in:
  9. 9
    Geographical distribution of large cities and small cities.

    Geographical distribution of large cities and small cities. by Saul Estrin (8629173)

    Published 2024
    “…The Figure reveals two patterns: 1) the maximum level of innovation is higher in large cities (2.53) than in small cities (2.02); 2) among large cities in <b>a</b>, innovation levels in general decrease with nightlight density. …”
    Save to List
    Saved in:
  10. 10
    Innovation, nightlights and a continuous measure of city size.

    Innovation, nightlights and a continuous measure of city size. by Saul Estrin (8629173)

    Published 2024
    Save to List
    Saved in:
  11. 11
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: